StockNews.com upgraded shares of Phibro Animal Health (NASDAQ:PAHC – Free Report) from a buy rating to a strong-buy rating in a research note published on Wednesday.
Other analysts also recently issued reports about the company. JPMorgan Chase & Co. initiated coverage on Phibro Animal Health in a research report on Tuesday, September 10th. They set a “neutral” rating and a $22.00 target price on the stock. Barclays boosted their price objective on shares of Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a research report on Tuesday, November 12th. Bank of America upped their price target on shares of Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a report on Friday, August 30th. Finally, Morgan Stanley lifted their price objective on Phibro Animal Health from $20.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $20.50.
Check Out Our Latest Stock Report on PAHC
Phibro Animal Health Trading Down 4.8 %
Phibro Animal Health Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Wednesday, December 18th. Investors of record on Wednesday, November 27th were given a dividend of $0.12 per share. The ex-dividend date was Wednesday, November 27th. This represents a $0.48 dividend on an annualized basis and a yield of 2.26%. Phibro Animal Health’s dividend payout ratio (DPR) is currently 111.63%.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of PAHC. Brandes Investment Partners LP lifted its holdings in shares of Phibro Animal Health by 1.2% during the 2nd quarter. Brandes Investment Partners LP now owns 2,405,629 shares of the company’s stock worth $40,521,000 after acquiring an additional 29,071 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Phibro Animal Health by 5.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 775,470 shares of the company’s stock valued at $13,005,000 after buying an additional 42,086 shares during the period. Acadian Asset Management LLC grew its stake in shares of Phibro Animal Health by 6.3% during the 2nd quarter. Acadian Asset Management LLC now owns 717,506 shares of the company’s stock valued at $12,027,000 after buying an additional 42,299 shares during the period. Dana Investment Advisors Inc. increased its holdings in shares of Phibro Animal Health by 17.2% during the 2nd quarter. Dana Investment Advisors Inc. now owns 513,926 shares of the company’s stock worth $8,619,000 after buying an additional 75,546 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Phibro Animal Health by 5.7% in the 3rd quarter. Geode Capital Management LLC now owns 507,469 shares of the company’s stock worth $11,430,000 after buying an additional 27,201 shares during the period. 99.34% of the stock is currently owned by institutional investors and hedge funds.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
Recommended Stories
- Five stocks we like better than Phibro Animal Health
- What Are Dividend Contenders? Investing in Dividend Contenders
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- Investing In Automotive Stocks
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- Earnings Per Share Calculator: How to Calculate EPS
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.